Clearmind Medicine Ownership
| CMND Stock | USD 1.38 0.01 0.73% |
Shares in Circulation | First Issued 2016-06-30 | Previous Quarter 3.6 M | Current Value 4.3 M | Avarage Shares Outstanding 1.7 M | Quarterly Volatility 3.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Clearmind |
Clearmind Stock Ownership Analysis
About 16.0% of the company shares are held by institutions such as insurance companies. The book value of Clearmind Medicine was currently reported as 0.87. The company recorded a loss per share of 1.69. Clearmind Medicine Common had not issued any dividends in recent years. The entity had 1:30 split on the 28th of November 2023. For more info on Clearmind Medicine Common please contact the company at 604 260 1566 or go to https://www.clearmindmedicine.com.Besides selling stocks to institutional investors, Clearmind Medicine also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Clearmind Medicine's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Clearmind Medicine's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Clearmind Medicine Quarterly Liabilities And Stockholders Equity |
|
Only 1.48% of Clearmind Medicine Common are currently held by insiders. Unlike Clearmind Medicine's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Clearmind Medicine's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Clearmind Medicine's insider trades
Clearmind Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Clearmind Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clearmind Medicine Common backward and forwards among themselves. Clearmind Medicine's institutional investor refers to the entity that pools money to purchase Clearmind Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gotham Asset Management, Llc | 2024-09-30 | 339 K | Advisorshares Investments, Llc | 2024-09-30 | 170.6 K | Ubs Group Ag | 2024-09-30 | 141.3 K | Cornerstone Wealth Group, Llc | 2024-12-31 | 20 K | Citadel Advisors Llc | 2024-09-30 | 17.7 K | Hrt Financial Llc | 2024-09-30 | 12.8 K | Royal Bank Of Canada | 2024-09-30 | 569 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 |
Clearmind Medicine Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clearmind Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clearmind Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clearmind Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lamadrid David over three weeks ago Disposition of tradable shares by Lamadrid David of Clearmind Medicine subject to Rule 16b-3 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.